Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit

NCT ID: NCT07259421

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.

This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Taurolidine Lock Solution

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
* Patient not opposed to participating in this research.

Exclusion Criteria

* Patient not speaking French
* Patient under guardianship or conservatorship
* Patient with major neurocognitive disorders
* Patient with severe hearing impairment
* Patient who do not have a telephone
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Cordélia SALOMEZ-IHL, pharmacist

Role: CONTACT

+ 33 (0)4 76 76 85 27

Aida MANDZO, clinical research associate

Role: CONTACT

+33 (0)4 76 76 68 16

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

38RC25.0315.

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Midlines and Thrombophlebitis
NCT03725293 COMPLETED NA